Elastic NV vs State Street SPDR S&P Biotech ETF — how do they compare? Elastic NV trades at $76.41 (market cap $7.94B), while State Street SPDR S&P Biotech ETF trades at $159.24. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ESTC | XBI | |
|---|---|---|
Market Cap | $7.94B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $94.47 | $164.28 |
52-Week Low | $43.30 | $86.92 |
Enterprise Value | $7.16B | — |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $75.88, down 0.58% on the day, with a bullish technical outlook supported by moving averages and strong institutional interest. Recent earnings beats and a projected net profit margin of 21.14% for 2026 highlight improving fundamentals, while collaborations with OpenAI and AWS security distinctions underscore strategic growth. The stock faces headwinds from high valuation multiples and a negative net income in 2025.
The outlook remains positive given analyst consensus and product innovations, but risks include elevated P/E and EV/EBITDA ratios, potential legal scrutiny, and competitive pressures. Upside is supported by a $106 high price target, though investor caution is warranted near-term due to overbought RSI levels.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Trailing returns across standard periods
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →